J&J axes Bavarian Nordic pact for HPV and hep B vax, keeps 2 other programsnews2022-05-09T13:53:25+00:00May 9th, 2022|FierceBiotech|
Investors flip-flop on Nykode’s cancer vaccine data dropnews2022-05-09T10:36:18+00:00May 9th, 2022|FierceBiotech|
Another Oxurion eye disease drug flunks phase 2, leaving biotech all-in on last prospectnews2022-05-09T09:31:11+00:00May 9th, 2022|FierceBiotech|
UPDATE: VistaGen says regulators couldn’t sniff out abuse potential of its nasal spray for social anxietynews2022-05-06T14:32:28+00:00May 6th, 2022|FierceBiotech|
With Sarepta in its sights, PepGen prices IPO to fund DMD trialsnews2022-05-06T11:16:46+00:00May 6th, 2022|FierceBiotech|
Bye-bye: Xencor culls 2 bispecifics after early-phase solid tumor data underwhelmnews2022-05-06T10:14:39+00:00May 6th, 2022|FierceBiotech|
Orion aims to challenge Vertex with new pain management licensing dealnews2022-05-06T10:02:27+00:00May 6th, 2022|FierceBiotech|
After layoffs, BridgeBio turns to dealmaking for up to 6 drugsnews2022-05-05T18:20:50+00:00May 5th, 2022|FierceBiotech|
Chutes & Ladders—Biogen CEO Vounatsos steps down amid company overhaul following Aduhelm blundernews2022-05-05T17:26:25+00:00May 5th, 2022|FierceBiotech|
Intellia puts pedal to the metal as 3 new candidates prepped for clinicnews2022-05-05T14:26:39+00:00May 5th, 2022|FierceBiotech|
